SEARCH

SEARCH BY CITATION

References

  • 1
    Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22: 115168.
  • 2
    Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999; 57: 92130.
  • 3
    Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 129536.
  • 4
    Cox PJ, Ryan DA, Hollis FJ et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28: 77280.
  • 5
    Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48: 42432.
  • 6
    Bolton GC, Keogh JP, East PD, Hollis FJ, Shore AD. The fate of a thiazolidinedione antidiabetic agent in rat and dog. Xenobiotica 1996; 26: 62736.
  • 7
    Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14: 1334.
  • 8
    Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 91528.
  • 9
    Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 11180.
  • 10
    Reunanen A, Kangas T, Martikainen J, Klaukka T. Nationwide survey of comorbidity, use, and costs of all medications in Finnish diabetic individuals. Diabetes Care 2000; 23: 126571.
  • 11
    Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J. Drug interactions of paclitaxel metabolism in human liver microsomes. J Chemother 2003; 15: 26674.
  • 12
    Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO. The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 2000; 50: 57380.
  • 13
    Park JY, Kim KA, Kang MH, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004; 75: 15762.
  • 14
    Miller AK, DiCicco RA, Freed MI. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. Clin Ther 2002; 24: 106271.
  • 15
    Miller AK, Inglis AM, Culkin KT, Jorkasky DK, Freed MI. The effect of acarbose on the pharmacokinetics of rosiglitazone. Eur J Clin Pharmacol 2001; 57: 1059.
  • 16
    Rao MN, Mullangi R, Katneni K et al. Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. J Clin Pharmacol 2002; 42: 6705.
  • 17
    Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003; 46: 131923.
  • 18
    Krishnaiah YS, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 1994; 37: 2057.
  • 19
    Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 56675.
  • 20
    Nadin L, Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol 1999; 58: 12018.
  • 21
    Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000; 28: 130310.
  • 22
    Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002; 300: 399407.
  • 23
    Yoon YR, Shon JH, Kim MK et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 27780.
  • 24
    Cho J, Suh Y, Lee J et al. Identification of polymorphism in human CYP2C8 gene by two-dimensional gel scanning in healthy Koreans. Clin Pharmacol Ther 2003; 73: P41.
  • 25
    Avandia® (GlaxoSmithKline). PDR Electronic Library™ 2003. Montvale, NJ: Thomson Medical Economics, 2003: 1.
  • 26
    Watanabe I, Tomita A, Shimizu M et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2003; 73: 43555.
  • 27
    Otto C, Lehrke M, Goke B. Novel insulin sensitizer: pharmacogenomic aspects. Pharmacogenomics 2002; 3: 99116.
  • 28
    Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003; 78: 108891.
  • 29
    Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002; 22: 9249.
  • 30
    Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 2001; 35: 1234.
  • 31
    Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 2003; 46: 28890.
  • 32
    Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol 2001; 108: S234S242.
  • 33
    Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998; 18: 8397.
  • 34
    Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 91528.